A new bispyrroloiminoquinone alkaloid, tsitsikammamine C (1), displayed potent in vitro antimalarial activity with IC 50 values of 13 and 18 nM against chloroquinesensitive (3D7) and chloroquine-resistant (Dd2) Plasmodium falciparum, respectively. Tsitsikammamine C (1) displayed selectivity indices > 200 against HEK293 cells and inhibited both ring and trophozoite stages of the malaria parasite lifecycle. Previously reported compounds, makaluvamines J (2), G (3), L (4), K (5) and damirones A (6) and B (7) were also isolated from the same marine sponge (Zyzzya sp.). Compounds 2-4 displayed potent growth inhibitory activity (IC 50 values <100 nM) against both P. falciparum lines and only moderate cytotoxicity against HEK293 cells (IC 50 value ~1-4 µM). Makaluvamine G (3) was not toxic to mice and suppressed parasite growth in P. berghei-infected mice following subcutaneous administration at 8 mg/kg/day.
INTRODUCTION
Malaria is an infectious disease caused by parasites belonging to the genus Plasmodium. It is estimated that over 3.2 billion people living in tropical and subtropical regions of the world, such as Sub-Saharan Africa, Central and South America, the Middle East, India and South East Asia are at risk from this disease. 1 Approximately 400 million clinical cases and 800,000
deaths are recorded annually, with more than 90% of malaria cases and the majority of malaria deaths occurring in Sub-Saharan Africa. 1 The frontline defence against malaria is drug prophylaxis or treatment, however, this is under threat due to parasite drug resistance 2 or decreased clinical efficacy of all antimalarial drugs currently used. 3, 4 Consequently, new antimalarial drugs are urgently needed in order to combat the global problem of parasite drug resistance.
The basis for the wide ranging biological activity of natural products can be explained by the similarity of the biosynthetic imprint, the molecular recognition between substrate and biosynthetic enzyme, and the natural product binding motif, the molecular recognition between a ligand and its therapeutic target, that led to the concept of protein fold topology (PFT). 5 PFT describes cavity recognition points unrelated to fold and sequence similarity, and defines a natural product's ability to recognize biology space. [6] [7] [8] Natural products have played a key role in antimalarial drug discovery and therapy. [9] [10] [11] [12] Well-known antimalarial natural products include quinine and artemisinin, which were first isolated from the South-American "quinine bark" (Cinchona succiruba) and the Chinese "sweet wormwood" (Artemisia annua), respectively. 13, 14 Numerous antimalarial drugs, such as artesunate, artemether, chloroquine, mefloquine, and halofantrine, have all been developed based on the pharmacophore present in quinine or artemisinin. 14, 15 Artemisinin-based combination therapy (ACT) is currently recommended for first-line treatment of P. falciparum malaria worldwide. However, recent reports of decreased efficacy of the ACT artesunate plus mefloquine and artesunate monotherapy in Western Cambodia is of immense concern. 4 Furthermore, poor safety profiles and undesirable side-effects of many current antimalarials are additional reasons for the need of new small molecule therapies.
In efforts to identify drug-like natural products following high-throughput screening (HTS)
campaigns, we have shown it is possible to develop a library of drug-like natural products. 16 In order to increase the diversity, we recently reported a procedure to capture natural products with LogP < 5 in extracts. 17 The extracts of over 18,000 marine and terrestrial biota samples were then fractionated (11 fractions collected per sample). In this study we undertook HTS 18 of the pre-fractionated natural product library in order to identify new antimalarial lead compounds. Analysis of the HTS data identified five fractions derived from the marine 27 In a similar manner, cytotoxicity data for makaluvamines A-F against xrs-6 cells had IC 50s in the range of 0.08-13.49 µM. 28 The pyrroloiminoquinone substructure has not only been isolated from Zyzzya spp. 19, 27, [29] [30] [31] but have also routinely been purified from sponges belonging to the genera Batzella, [32] [33] [34] [35] Damiria, 21 Histodermella, 20 Latrunculia, [36] [37] [38] [39] [40] Negombata, 41 Prianos, Spongosorites, 42 Higginsia 42 and Tsitsikamma. 22, 23 Other marine organisms such as ascidians, have also been the sources of this structure class. 43 Pyrroloquinone-derived natural products have been shown to display a remarkable array of biological activities, and as a result a number of synthetic methodologies have been developed to prepare either the natural products or analogs. [44] [45] [46] Tsitskammamines A and B also belong to this important structure class; these metabolites were first isolated from a latrunculid sponge collected in South African waters, 23 and were shown to exhibit cytotoxicity and mammalian topoisomerase I inhibition. Compounds 1-7 were all tested in vitro against the chloroquine-sensitive 3D7 and chloroquine-resistant Dd2 P. falciparum lines. The Dd2 line is also mefloquine-resistant.
Cytotoxicity data was also obtained for 1-7 using a human embryonic kidney cell line (HEK293). In order to assess the drug-like and lead-like properties of alkaloids 1-7, in silico physicochemical properties were calculated using Instant JChem software, 49 and the data compared to Lipinski's drug-like "rule of five", 50 and Hann and Oprea's lead-like criteria. 51 All compounds complied with Lipinski's rules (log P <5, HBA < 10, HBD <5, MW <500), and Hann-Oprea guidelines (log P <4, HBA <9, HBD <5, MW <460, rotatable bonds <10).
The biological activity, selectivity indices, and in silico calculated physicochemical properties of compounds 1-7 are detailed in Table 2 . Comparing the makaluvamine analogs 2-5 to the simplified 1,2-dicarbonyl tricyclic compounds, damirones A (6) and B (7), showed an almost complete loss of malaria growth inhibition, indicating that the iminoquinone of 2-5 rather than the 1,2-dicarbonyl of 6-7 is essential for antimalarial activity.
Furthermore, when comparing the biological data of 2-5 that all have more than two rotatable bonds in their N-alkyl side chain to tsitsikammamine C (1) the data indicates that restricting the configuration of the pendant phenol motif improved activity slightly. This suggests that an out-of-plane conformation of the phenol aromatic ring due to steric interactions with the methyl on the iminium nitrogen is preferred and establishes the likely preferred conformation.
Compounds 1-3 were also examined for stage-specific activity against ring versus trophozoite stage P. falciparum 3D7 parasites following exposure times of 4, 6, and 10 h. Sufficient quantities of compounds 2 and 3 were available for additional biological studies to be performed. First, in vitro studies in hepatic microsomes were conducted to assess the extent of metabolic degradation and then in vivo studies were conducted in mice to determine the systemic exposure following subcutaneous administration. In both human and mouse liver microsomes, compound 3 was more rapid degraded compared than 2, suggesting that the in vivo hepatic clearance would be higher for 3 than for 2 (Table 3 ). There was also evidence for a higher rate of degradation of 2 in mouse microsomes relative to human. In vivo studies were conducted using an abbreviated sampling protocol with only three time points and two mice per time point due to the limited availability of each of the compounds. Each compound was administered at a dose level of 8 mg/kg in 0.1 mL of a formulation composed of 5-7 % (v/v) DMSO in saline. At this formulation concentration (~2.2 mg/mL for 2 and ~2.6 mg/mL for 3)
compound 2 was a solution while 3 was a fine suspension. Plasma concentrations of 2 reached approximately 1.7 µM at 1 h post-dose and declined over the 4 h post-dose sampling period.
In comparison, plasma concentrations of 3 were consistently low (less than 0.04 µM) over the same duration. Even with this limited data, it was evident that the systemic exposure of 3 was markedly lower than that for 2 ( Figure 4 ). Assuming that hepatic metabolism is a major determinant of the in vivo clearance of these two compounds, this result is consistent with the in vitro microsomal stability data which suggested 2 was more metabolically stable than 3.
Furthermore, the observed differences in plasma exposure may also result from differences in the rate and/or extent of absorption, given that 2 was dosed as a solution, whereas 3 was dosed as a suspension.
Based on the DMPK data, in vivo tolerability and efficacy studies were subsequently undertaken on makaluvamines J (2) and G (3). Due to the limited supply of each compound, the maximum dosage assessed for tolerability was 8 mg/kg/day for 4 days. No physical distress was seen in healthy mice administered subcutaneously with makaluvamine J up to 4 mg/kg/day, however at 8 mg/kg/day the mice showed reduced activity, ruffled coat and weight loss >10%. In contrast, makaluvamine G was well tolerated in mice at 8 mg/kg/day. When compound 2 was tested for efficacy at 4 mg/kg/day, no parasite suppression was observed in mice infected with P. berghei using the Peter's 4-day test. 52 In contrast, when administered at 8 mg/kg/day, compound 3 suppressed P. berghei infection by 10% on day 1 post infection (p.i.), and by 35%, 47%, and 48% at day 2, 3, and 4 p.i., respectively, relative to the control group. The comparator, chloroquine, suppressed P. berghei infection by 35% at day 4 p.i., which is in accord with previous findings, with ED 50 (effective dose at 50% suppression) of 1.9 mg/kg/day. 52 The apparent in vivo activity of 3 is interesting in light of the low exposure in mice after oral dosing, raising the possibility that there could be an active metabolite for this compound. Further work to characterize the metabolic profile of 3 would be required to explore this hypothesis.
The in vivo data for makaluvamine G (3) indicates that this structure class has promising antimalarial activity. The new metabolite tsitsikammamine C (1) displayed 2-3 fold greater in vitro potency, had selectivity indices in excess of 200 and inhibited both ring and trophozoite stages of the parasite life cycle compared to makaluvamine G (3) that had selectivity indices around 50 and mainly inhibited the trophozoite stage. Synthesis focused on the tsitsikammamine motif is warranted in order to enable further antimalarial evaluation.
EXPERIMENTAL SECTION
General Experimental Procedures. UV spectra were recorded on a Jasco V-650 UV/Vis spectrophotometer. NMR spectra were recorded at 30 ºC on Varian INOVA 500 and 600
MHz NMR spectrometers. The latter spectrometer was equipped with a triple resonance cold (0.1% TFA)/10% CH 3 OH (0.1% TFA) were initially employed for the first 10 min, then a linear gradient to CH 3 OH (0.1% TFA) was run over 40 min, followed by isocratic conditions of CH 3 OH (0.1% TFA) for a further 10 min, all at a flow rate of 9 mL/min. Sixty fractions (60 × 1 min) were collected from time = 0 min then analyzed using the antimalarial bioassay.
Activity was identified in fractions 31-39. 1 H NMR and LRESIMS analysis of these bioactive fractions showed that fraction 32 contained pure makaluvamine J (2, 2.3 mg, 0.023% dry wt), while fraction 31 (4.6 mg) and fractions 36-39 (21.6 mg) contained semi-pure mixtures of related natural products. Both of these fractions were further purified by semi-preparative C 18 HPLC using identical conditions to those described above to afford tsitsikammamine C (1, 0.2 mg, 0.002% dry wt), and makaluvamine G (3, 0.4 mg, 0.004% dry wt). Further large-scale extraction and isolation work was subsequently undertaken on the remaining 145 g of the freeze-dried and ground sponge material. Identical extraction protocols to those used for the 10 g sample were employed, albeit larger volumes of solvent were used. The resulting CH 2 Cl 2 /CH 3 OH and CH 3 OH extractions were combined then subjected to extensive C 18 bonded silica HPLC (CH 3 OH/H 2 O/0.1% TFA), using MS and UV data to guide purification.
This yielded more of tsitsikammamine C (1, 9.0 mg, 0.006% dry wt), makaluvamines J (2, 30 mg, 0.021% dry wt) and G (3, 24 mg, 0.017% dry wt), along with the additional, and previously reported compounds, makaluvamines K (4, 3.0 mg, 0.002% dry wt) and L (5, 6.9 mg, 0.004% dry wt), and damirones A (6, 3.3 mg, 0.002% dry wt) and B (7, 0.7 mg, 0.0005% dry wt). 
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ppm).
In vitro Antimalarial Assay. Compounds were incubated in the presence of 2 or 3% parasitemia (3D7 or Dd2) and 0.3% hematocrit in a total assay volume of 50 µL, for 72 h at 
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